Efficacy and Safety of Guihuang Formula in Treating Type III Prostatitis Patients with Dampness-Heat and Blood Stasis Syndrome: A Randomized Controlled Trial

• Published in: Chinese journal of integrative medicine 2022-10, Vol.28 (10), p.879-884
• Main Authors: Liu, Sheng-jing, Deng, Ying-jun, Zeng, Yin, Zhao, Ming, Guo, Jun, Gao, Qing-he
• Format: Article
• Language: English
• Subjects: Chronic Disease; Hot Temperature; Humans; Lecithins; Male; Medicine; Medicine & Public Health; Original; Original Article; Pain; Prostatitis - drug therapy; Quality of Life; Tamsulosin
• ISSN: 1672-0415; 1993-0402; 1993-0402
• DOI: 10.1007/s11655-022-3467-1

Objective To observe the efficacy and safety of Guihuang Formula (GHF) in treating patients with type III prostatitis and Chinese medicine syndrome of dampness-heat and blood stasis. Methods Sixty-six patients diagnosed with type III prostatitis with dampness-heat and blood stasis syndrome were randomly divided into the treatment group (GHF) and the control group (tamsulosin) using a random number table, with 33 cases each group. The treatment group received GHF twice a day, and the control group received tamsulosin 0.2 mg once daily before bedtime. Patients in both groups received treatment for 6 weeks and was followed up for 2 weeks. The outcomes included the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score, Chinese Medicine Symptoms Score (CMSS), expressed prostatic secretions (EPS) and adverse events (AEs). Results After treatment, the NIH-CPSI total score and domain scores of pain discomfort, urination and quality of life decreased significantly from the baseline in both groups ( P